Medrio and Avance Clinical Reach 150 Clinical Trials Partnership Milestone

Share Article

Medrio, Inc and Avance Clinical have surpassed 150 Phase I clinical studies conducted together over an eight-year period.

“Medrio has always been a wonderful partner to Avance Clinical. We’re always impressed by not only their speed and flexibility but also their support. I look forward to the continued success and growth of our partnership,” said Yvonne Lungerhausen, CEO, Avance Clinical.

Medrio, Inc., the leading provider of eClinical technology to pharmaceutical, biotech, medical device, diagnostics, and animal health markets, and Avance Clinical, the leading Australian CRO for biotechs have reached a milestone of supporting 150 clinical trials together. Medrio and Avance Clinical’s successful partnership began in 2012 on a Phase I study with 103 patients and 14 sites, with Avance Clinical being Medrio’s first partner in Australia.

Avance Clinical has utilized Medrio’s electronic data capture (EDC) solution successfully for the past eight years supporting 158 Phase I studies, 6,047 patients, and 236 sites. The HRECs usual review cycle in Australia, which takes only 4 to 8 weeks, coupled with Medrio’s ability to achieve FPI in less than three weeks is a perfect combination for accelerating study starts, a critical component to Phase I trials.

“Medrio has always been a wonderful partner to Avance Clinical. In addition to their EDC, we’ve used their ePRO and Direct Capture solutions, and we’re always impressed by not only their speed and flexibility but also their support. We know that if we have a question or need assistance that it will be addressed immediately and resolved quickly. Our partnership continues to flourish through ongoing clinical trials. We also recently had a great conversation with Medrio on their podcast, Trial Talks, about Australia’s unique position in the midst of COVID-19. I look forward to the continued success and growth of our partnership,” said Yvonne Lungerhausen, CEO, Avance Clinical.

In July 2020 Medrio will launch Trial Talks, a clinical trials podcast series. Hosted by Medrio thought leaders, Trial Talks season one will focus on industry trends and challenges, unique solutions, and the perseverance of the industry through one of our toughest challenges, COVID-19. Trial Talks season 1, episode 1 “Why Clinical Trials are Thriving in Australia” will focus on how Avance Clinical prepared for the pandemic, what tools they leveraged that allowed trial continuation, and why clinical trials are currently thriving in the region.

“I’ve always been data-driven, and reaching the 150 trials milestone speaks volumes about Medrio and Avance’s relationship. Trust is earned, and I’d like to think that we’ve shown that we offer not only sophisticated clinical trial technology but also pride in our work. Our support team is available 24/7 and I am always proud to hear our customers speak so highly of them. At Medrio we always have the patients in mind, and the faster we can get a trial up and running or provide support, the faster the patients in need will have the drugs, therapies, or devices that they need. I enjoyed interviewing Yvonne Lungerhausen (CEO) and Sandrien Louwaars (Director of Business Development Operations) for the first Trial Talks podcast episode. It was fascinating to hear how Australia and New Zealand are operating in the midst of a global pandemic, and it highlights the perseverance of the industry and the Golden Age of pharma,” explained Mike Novotny, CEO, Medrio.

About Medrio
Medrio is the leading provider of eClinical technology for pharma, device, and diagnostics clinical trials. Founded in 2005, the company’s cloud-based EDC, Direct Data Capture, eConsent, and ePRO solutions deliver fast, flexible, and easy-to-use tools for the collection and management of clinical data and patient-reported outcome responses. Study sponsors and Contract Research Organizations have used Medrio extensively in clinical trials across a wide array of therapeutic areas, with notable success in oncology, infectious disease, and more. Medrio has extensive experience in all study phases and leads the market in early-phase trials. The company serves over 600 customers globally, with headquarters in San Francisco and offices in numerous domestic and international locations. For more information, please visit

About Avance Clinical
Australia’s Avance Clinical has more than 20-years of experience and is now one of Australia’s leading Contract Research Organizations. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world.
Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team.
The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.
Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups. Visit for more information.
Other benefits include:
1. The Government R&D grant means up to 43.5% rebate on clinical trial spend
2. Telehealth pivot during COVID-19 pandemic – speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 – 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialized patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia’s counter-flu and allergy seasons

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jillian Tygh
Email >
Follow >
Visit website